These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 19176890)
1. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Sachidanandam K; Hutchinson JR; Elgebaly MM; Mezzetti EM; Dorrance AM; Motamed K; Ergul A Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R952-9. PubMed ID: 19176890 [TBL] [Abstract][Full Text] [Related]
2. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Sachidanandam K; Portik-Dobos V; Kelly-Cobbs AI; Ergul A Can J Physiol Pharmacol; 2010 Jun; 88(6):616-21. PubMed ID: 20628426 [TBL] [Abstract][Full Text] [Related]
3. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Sachidanandam K; Portik-Dobos V; Harris AK; Hutchinson JR; Muller E; Johnson MH; Ergul A Diabetes; 2007 Nov; 56(11):2753-8. PubMed ID: 17670915 [TBL] [Abstract][Full Text] [Related]
4. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Matsumoto T; Ishida K; Nakayama N; Kobayashi T; Kamata K Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1388-97. PubMed ID: 19286964 [TBL] [Abstract][Full Text] [Related]
5. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Sachidanandam K; Elgebaly MM; Harris AK; Hutchinson JR; Mezzetti EM; Portik-Dobos V; Ergul A Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2743-9. PubMed ID: 18424628 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. Sachidanandam K; Hutchinson JR; Elgebaly MM; Mezzetti EM; Wang MH; Ergul A J Pharmacol Exp Ther; 2009 Jan; 328(1):123-30. PubMed ID: 18941121 [TBL] [Abstract][Full Text] [Related]
7. Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes. Abdelsaid M; Ma H; Coucha M; Ergul A Life Sci; 2014 Nov; 118(2):263-7. PubMed ID: 24434796 [TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Harris AK; Hutchinson JR; Sachidanandam K; Johnson MH; Dorrance AM; Stepp DW; Fagan SC; Ergul A Diabetes; 2005 Sep; 54(9):2638-44. PubMed ID: 16123352 [TBL] [Abstract][Full Text] [Related]
9. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Harris AK; Elgebaly MM; Li W; Sachidanandam K; Ergul A Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1213-9. PubMed ID: 18287215 [TBL] [Abstract][Full Text] [Related]
10. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Song W; Ergul A Cardiovasc Diabetol; 2006 Feb; 5():3. PubMed ID: 16503991 [TBL] [Abstract][Full Text] [Related]
12. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Abdelsaid M; Kaczmarek J; Coucha M; Ergul A Life Sci; 2014 Nov; 118(2):268-73. PubMed ID: 24447630 [TBL] [Abstract][Full Text] [Related]
13. Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and alpha1-adrenoceptor-mediated vasoconstriction in Type 2 diabetes. Bender SB; Klabunde RE Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2281-8. PubMed ID: 17660396 [TBL] [Abstract][Full Text] [Related]
15. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Sachidanandam K; Harris A; Hutchinson J; Ergul A Exp Biol Med (Maywood); 2006 Jun; 231(6):1016-21. PubMed ID: 16741041 [TBL] [Abstract][Full Text] [Related]
16. Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes. Li W; Kelly-Cobbs AI; Mezzetti EM; Fagan SC; Ergul A Can J Physiol Pharmacol; 2010 Aug; 88(8):788-95. PubMed ID: 20725136 [TBL] [Abstract][Full Text] [Related]
17. Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system. Yasir A; Hardigan T; Ergul A Life Sci; 2016 Aug; 159():76-82. PubMed ID: 26944436 [TBL] [Abstract][Full Text] [Related]
18. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Park JB; Schiffrin EL Hypertension; 2001 Jun; 37(6):1444-9. PubMed ID: 11408393 [TBL] [Abstract][Full Text] [Related]
19. Aminoguanidine normalizes ET-1-induced aortic contraction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats by suppressing Jab1-mediated increase in ET(A)-receptor expression. Nemoto S; Taguchi K; Matsumoto T; Kamata K; Kobayashi T Peptides; 2012 Jan; 33(1):109-19. PubMed ID: 22154739 [TBL] [Abstract][Full Text] [Related]
20. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. Kelly-Cobbs AI; Harris AK; Elgebaly MM; Li W; Sachidanandam K; Portik-Dobos V; Johnson M; Ergul A J Pharmacol Exp Ther; 2011 Apr; 337(1):9-15. PubMed ID: 21205912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]